The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers-Reference-Cited by-同舟云学术

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Published:2021-02 Issue:2 Volume:32 Page:269-278
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Saturno G.,Lopes F.,Niculescu-Duvaz I.,Niculescu-Duvaz D.,Zambon A.,Davies L.,Johnson L.,Preece N.,Lee R.,Viros A.,Holovanchuk D.,Pedersen M.,McLeary R.,Lorigan P.,Dhomen N.,Fisher C.,Banerji U.,Dean E.,Krebs M.G.,Gore M.,Larkin J.,Marais R.,Springer C.

Funder

Wellcome Trust

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference33 articles.

1. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies;Garrido-Laguna;Nat Rev Clin Oncol,2015

2. A review of the evolution of systemic chemotherapy in the management of colorectal cancer;Gustavsson;Clin Colorectal Cancer,2015

3. RAS proteins and their regulators in human disease;Simanshu;Cell,2017

4. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future;Chan;Transl Lung Cancer Res,2015

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting RAF dimers in RAS mutant tumors: From biology to clinic;Acta Pharmaceutica Sinica B;2024-05

2. The intricate dance of tumor evolution: Exploring immune escape, tumor migration, drug resistance, and treatment strategies;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-04

3. Intraoperative Lymph Node Management in Patients with Stage I NSCLC;Advances in Clinical Medicine;2024

4. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022;ACS Omega;2023-07-26

5. KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression;Frontiers in Cell and Developmental Biology;2023-04-20